posted
volume kinda blows right now which is what's keeping me away for the moment. i do like this play's potential though. somewhat currently in the middle of the rise to a double neck / shoulder rebound. and, yes, thus .08 seems reasonable.
-------------------- Cashing checks in two forms: Money and Reality
GLTA, The Phat Man Posts: 1236 | Registered: Apr 2006
| IP: Logged |
posted
I picked up a few more shares before I have to roll out for the day.....I feel quite confident in CalbaTech and the things they have in the works right now!! theres no way this stays under a dime much longer imo.
Adult stem cell biotechs: better prospects, less controversy Several outfits are in the advanced stages of testing adult stem cells to help repair damaged bones as well as heart and breast tissue., By Aaron Smith, CNNMoney.com staff writer August 9 2006: 3:37 PM EDT
New York, NY (LifeNews.com) -- More financial analysts are saying that biotech firms that work with adult stem cell research are better prospects for investors than those working with embryonic stem cells. The news comes after lobbyists and lawmakers condemned President Bush for focusing federal taxpayer dollars on adult stem cell research. Last week, LifeNews.com reported on one investment advisor who said companies relying on adult stem cells are more likely to provide payoffs for investors. Other a nalysts say that adult stem cells companies like Osiris, Cytori, Aastrom should be monitored by investors for possible buys because they are more likely to get therapies on the market than companies using embryonic stem cells.
"From a Wall Street perspective, adult stem cells are a much better investment," Stephen Dunn of Dawson James Securities, told CNN. "These are the guys who are going to be in the news in 2007 and 2008."
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," Dunn added. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
While embryonic stem cell research has seen numerous failures with animals and may be a decade or more away from producing any human therapies, adult stem cell research has already yielded dozens of treatments -- some of which may be at the market within years.
The Baltimore-based Osiris Therapeutics initially offered stock on August 4 and already has a product on the market called Osteocel that helps rebuild damaged bones.
The company would have advanced further in promoting the product, CNN reports, if not for having a hard time finding enough donors of bone tissue to build up its stem cell inventory.
Thus, while some politicians clamor for more taxpayer dollars for embryonic stem cell research that may never help patients, funds for obtaining more bone tissue would help patients today.
Osiris has another adult stem cell product, Prochymal, which helps patients with a life-threatening affliction called Acute Graft versus Host Disease. The same drug is also being tested for use in treating Crohn's disease.
Stephan Brozak, analyst for WBB Securities, told CNN he likes the product and reports he's seen show patients have experienced "remarkable results."
The company is in the final stages of clinical trials and will soon be ready to submit the drug to the FDA in 2007.
Dunn tells CNN he's bullish on another company, Michigan-based Aastrom Biosciences, which also develops an adult stem cell therapy dealing with regrowing bone tissue.
Meanwhile, the San Diego biotech Cytori Therapeutics uses adult stem cells from fat to rebuild damaged tissue. Via a liposuction technology called Celution, the company is taking the cells from a patient and reinserting them into the patient's body at the point of the problem.
The process is also being used to help improve heart function in patients with severe coronary artery disease. That could be sent to the FDA for approval in 2008 and the liposuction procedure could be sent to the FDA next year.
WBB Securities' Brozak says the FDA approval process for these new therapies may take longer because the science is newer, but he says these companies have a good shot at bringing the products to market.
posted
E&E just released this!!! had a feeling the PR's release were related to our puppy!!
LOL...look what E&E just put out for CLBE....I e-mailed Paul both the news reports you guys posted here!!
CalbaTech (OTC BB: CLBE): Why It Is Smart to Be Involved in Collection of Adult Stem Cells
More Financial Analysis Say Adult Stem Cell Research Companies Better
by Steven Ertelt LifeNews.com Editor August 9, 2006
New York, NY (LifeNews.com) -- More financial analysts are saying that biotech firms that work with adult stem cell research are better prospects for investors than those working with embryonic stem cells. The news comes after lobbyists and lawmakers condemned President Bush for focusing federal taxpayer dollars on adult stem cell research. Last week, LifeNews.com reported on one investment advisor who said companies relying on adult stem cells are more likely to provide payoffs for investors.
"From a Wall Street perspective, adult stem cells are a much better investment," Stephen Dunn of Dawson James Securities, told CNN. "These are the guys who are going to be in the news in 2007 and 2008."
"Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well." Dunn added.
While embryonic stem cell research has seen numerous failures with animals and may be a decade or more away from producing any human therapies, adult stem cell research has already yielded dozens of treatments -- some of which may be at the market within years.
The company is in the final stages of clinical trials and will soon be ready to submit the drug to the FDA in 2007.
*****
Adult stem cell biotechs: better prospects, less controversy Several outfits are in the advanced stages of testing adult stem cells to help repair damaged bones as well as heart and breast tissue., By Aaron Smith, CNNMoney.com staff writer August 9 2006: 3:37 PM EDT
NEW YORK (CNNMoney.com) -- Embryonic stem cells might hold the secrets to curing paralysis and brain damage, but they've also garnered plenty of controversy with the anti-abortion lobby because they're harvested from embryos.
However, work using adult stem cells - which are donated by grown men and women - is not only free of such controversy, it's actually much closer to getting effective products on the market.
Work with adult stem cells isn't being held back by funding restraints and political opposition, analysts say.
"Embryonic stem cell research hasn't kept up pace with adult stem cell research," said Dunn. "Adult stem cell research is advancing so far you might not need embryonic stem cells. If the federal government is reluctant to put their money into it, then Wall Street is as well."
So while embryonic stem cell researchers are experimenting with rats, adult stem cell researchers have moved on to more advanced tests with humans. The embryonic-based stem cell treatments are probably a decade away, but the U.S. market could see its first adult-based stem cell treatments within the next couple of years.
Going in BIGTIME tomorrow morning. Once we see how good the 2nd QTR Financials are this is going to f'kn explode into the multi-pennies! .12 - .14 easily! The financials could be out any day now. No later than monday the 14th and as soon as TOMORROW!
posted
Is it just me or does it look like CLBE is forming a cup and handle on the chart? Looks like the handle is just finishing and the breakout is about to begin!
Posts: 14 | Registered: Jul 2006
| IP: Logged |
posted
CLBE: Launch Date 0f Aug 15th for Stem Cell Microbank
CalbaTech, Inc. (CLBE) announced that its wholly owned subsidiary, LifeStem, Inc. will begin operations of its Adult Stem Cell Microbank(TM) collection service on August 15th 2006.
8/10/06 8:10:55 AM *********.com: Price and Volume Alerts for Thursday August 10, 2006 - One Company Announces Launch Date for Stem Cell Microbank While Another Receives Vendor Setup and Fridge Tape(R) Purchase Order
posted
well heres what we have in the works....the stem cell banking will be underway on the 15th.....the expected positive financials can be released at anytime now....the MedSpa's will have 38 to 50 new locations opening before year end...the CEO made a clear statement that CalbaTech will be profitable in 2006....this is just some tidbits......everyone here by now should have at least a small position in CLBE or get in ASAP imo....this is not one to flip constantly.
posted
I have a AON tester sitting on the ask and not even getting anibble yet....just need more buying pressure and this will jump to .065 on just a few small buys imo.
posted
I guess I sorta expected it to rise a bit faster. Either way green is good. I'll take 5% a day.
-------------------- Before you criticize someone, try walking a mile in their shoes, then when you do, you'll be a mile away and have their shoes. Posts: 1450 | From: TX | Registered: Feb 2006
| IP: Logged |
posted
bid is looking even better now guys and this should only get stronger over the next week.CLBE is definitely one to have a core position in in the long run.....I have no doubt that this will be trading much much higher before year end.
posted
e-mail from Paul in response to my questions.
Quest Solver wrote:
Hi Paul....I was just wondering...when you send out an e-mail like this how many people does it reach? Is it also posted elsewhere as a PR or share holder info so that many in the public can see it?
TIA
Hank
We maintain two lists. One is for CalbaTech. Anyone who wants CalbaTech news releases, etc. is on that one. We also maintain a list of about 1,200 individuals, brokers, others who seem to have a taste for micro caps, who have had success with our clients, and who want this information. We send to them information when I think it particularly relevant. We assist circa 15 companies so I don't want to overwhelm anyone with everything. I hope this helps.
posted
Investors can take this to the bank: the promise and efficacy of stem cell therapies will ultimately trump the politics. The medical potential is simply too great to ease suffering, salvage patient lives and save the healthcare industry a massive slug of money. Not to mention throwing off some great investment opportunities. Over 70 companies --the vast majority of them small or microcaps-- are doing some amazing work on stem cell therapies.
We have recently unearthed a great smallcap biotech company that deals directly in this realm and plan to bring it to you in the next week or two. In the interim, it would be to your benefit to get to know the ins and outs of the stem cell landscape
Here’s a link to several other stem cell companies worldwide. http://www.stem-cell-companies.com/. Be advised, many are in their formative stages. Careful review is warranted. As in every new sector, not all will prosper or even survive.
Profits soon. Well, pretty soon.
Revenues from current stem cell initiatives should begin to bite in a meaningful way by 2009, exploding to almost $4 billion-plus by 2015. Beyond that, the sky is likely the limit. Investors who see the potential, now, will likely garner the best returns as the scenario unfolds.
Nearly $15 billion will be spent over the next decade on both embryonic and adult stem cell research/therapies. States, such as California, recently passed a contentious initiative (Proposition 71), which earmarks $3 billion --by way a pending bond issue-- over the next ten years for stem cell research. Other states are looking at California’s lead to acquire stem cell funding in an effort to make up the R&D shortfall that has resulted from limited federal participation.
On the threshold of greatness. And profits
We believe that investors are on the threshold of a whole new and extremely exciting genus of therapies. While acknowledging the controversy around this sector, the over-riding fact is that the formative science is just too compelling to ignore both for healthcare and especially those patients suffering debilitating disease.
Is it too early to consider stem cell investing? Would it have been too early to buy Microsoft years ago or to be an early investor with a young(er) Warren Buffett? That’s the type of long-term trend we believe is in the early process of unfolding for stem cell companies. For those investors who have the patience and risk tolerance, there will be some very exciting names coming forward, including those that we will illuminate for readers.
The Two Types of Stem Cells.
Stem cells differ from other kinds of cells in the body. All stem cells—regardless of their source—have three general properties: they are capable of dividing and renewing themselves for long periods; they are unspecialized; and they can give rise to specialized cell types.
Adult stem cells are thought to reside in a specific area of each tissue where they may remain quiescent (non-dividing) for many years until they are activated by disease or tissue injury. The adult tissues reported to contain stem cells include brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin and liver.
Globally, scientists are trying to find ways to grow adult stem cells in cell cultures and manipulate them to generate specific cell types so they can be used to treat injury or disease. Some examples of potential treatments include replacing the dopamine-producing cells in the brains of Parkinson's patients, developing insulin-producing cells for type I diabetes and repairing damaged heart muscle following a heart attack with cardiac muscle cells.
Embryonic stem cells as their name suggests, are derived from embryos after about five days. Specifically, these stem cells are derived from embryos that develop from eggs that have been fertilized in vitro —in an in-vitro fertilization clinic—and then donated for research purposes with the informed consent of the donors.
posted
the stem cell issue is constantly being looked at and debated and since there have been several variences of stem cell usage the banking system will have to be one part that will be constant since all the stems need to be secured.Once real successes start getting printed then you can bet that health insurance providers will be looking at individual stem cell banking to protect the insurance companies in the long run.Hell as stated here before it may end up being a requirement by the health insurance companies to secure policies....face it people this technology is not going away and is only going to be enhanced and refined.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
